This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Stassen, J. M. Articles by Collen, D. Search for Related Content PubMed PubMed Citation Articles by Stassen, J. M. Articles by Collen, D.

(Circulation. 1995;91:1330-1335.)
© 1995 American Heart Association, Inc.

Articles

Antithrombotic Effects of Thrombolytic Agents in a Platelet-Rich Femoral Vein Thrombosis Model in the Hamster

Jean Marie Stassen; Åke Nyström, MD, PhD; Marc Hoylaerts, PhD; Désiré Collen, MD, PhD

From the Department of Othopedics and Hand Surgery (J.M.S., A.N.), University Hospital of Umeå, Sweden; Division of Plastic Surgery (A.N.), University of Pittsburgh, Pa; and the Center for Molecular and Vascular Biology (J.M.S., M.H., D.C.), University of Leuven, Belgium.

Correspondence to Désiré Collen, MD, PhD, Center for Molecular and Vascular Biology, University of Leuven, Campus Gasthuisberg, O & N, Herestraat 49, B-3000 Leuven, Belgium.

Background The extent and mechanism of the antithrombotic properties of fibrin-selective and non–fibrin-selective thrombolytic agents have not yet been established.

Methods and Results The antithrombotic, thrombolytic, fibrinogenolytic, and pharmacokinetic properties of the following substances were determined in hamsters in the absence of conjunctive anticoagulant or antiplatelet therapy: recombinant tissue-type plasminogen activator (rTPA), recombinant single-chain urokinase-type plasminogen activator (rscu-PA), two-chain urokinase-type plasminogen activator (UK), with a rTPA deletion mutant lacking amino acids 6 to 173 and a mutation N184E (K₂Pt), a rTPA/rscu-PA chimeric plasminogen activator consisting of amino acids 1 to 3 and 87 to 274 of rTPA and amino acids 138 to 411 of rscu-PA (K₁K₂Pu), streptokinase (SK), and recombinant staphylokinase (STAR). The antithrombotic effect, defined as the intravenous dose required to reduce mural thrombus formation to 50% in a platelet-mediated femoral vein thrombosis model in the hamster, was 6±1, 5±2, 1±0.05, 2.5±0.2, 0.02±0.002, 1±0.09, and 2±0.3 mg/kg (mean±SEM), respectively. The amounts, given as intravenous infusion over 60 minutes that induced 50% clot lysis in a hamster pulmonary embolism model, were 0.18±0.03, 1.1±0.05, 0.9±0.13, 0.34±0.03, 0.04±0.003, 0.05±0.005, and 0.04±0.001 mg/kg, respectively, indicating that for most thrombolytic agents the antithrombotic dose is much higher than their thrombolytic dose. The fibrinogen levels, measured 40 minutes after bolus injection, were reduced to 50% of baseline with 3.1±0.2, 2.5±0.3, 1.2±0.08, 2.0±0.14, 1.7±0.65, 0.54±0.03, and 1.2±0.11 mg/kg, respectively. Mean residence times following intravenous bolus injection were: 18±1, 14±1, 100±10, 80±2, 20±3, and 34±5 minutes for rTPA, rscu-PA, K₂Pt, K₁K₂Pu, SK, and STAR, respectively. Regression analysis revealed a significant correlation of the antithrombotic effect with the fibrinogen breakdown (P=.006) but not with the thrombolytic potency or with the mean residence time.

Conclusions These observations support the hypothesis that thrombolytic therapy with fibrinogen-sparing agents requires the conjunctive use of anticoagulant and/or antiplatelet agents.

Key Words: thrombolysis • pharmacokinetics

This article has been cited by other articles:

				J.-C. Murciano, D. Harshaw, D. G. Neschis, L. Koniaris, K. Bdeir, S. Medinilla, A. B. Fisher, M. A. Golden, D. B. Cines, M. T. Nakada, et al. Platelets inhibit the lysis of pulmonary microemboli Am J Physiol Lung Cell Mol Physiol, March 1, 2002; 282(3): L529 - L539. [Abstract] [Full Text] [PDF]